SCIENTURE HOLDINGS INC (SCNX) Stock Fundamental Analysis
USA - NASDAQ:SCNX - US80880X1046 - Common Stock
0.5484 USD
-0.01 (-1.72%)
Taking everything into account, SCNX scores 1 out of 10 in our fundamental rating. SCNX was compared to 35 industry peers in the Health Care Technology industry. SCNX may be in some trouble as it scores bad on both profitability and health. SCNX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
SCNX had negative earnings in the past year.
SCNX had a negative operating cash flow in the past year.
In the past 5 years SCNX reported 4 times negative net income.
In the past 5 years SCNX always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -19.30%, SCNX is in line with its industry, outperforming 45.71% of the companies in the same industry.
SCNX has a Return On Equity of -25.86%. This is comparable to the rest of the industry: SCNX outperforms 57.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.3% | ||
| ROE | -25.86% | ||
| ROIC | N/A |
ROA(3y)-75.75%
ROA(5y)-69.08%
ROE(3y)-1244.95%
ROE(5y)-781.05%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 5.77%, SCNX is not doing good in the industry: 88.57% of the companies in the same industry are doing better.
SCNX's Gross Margin has declined in the last couple of years.
SCNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 5.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-54.95%
GM growth 5Y-41.74%
2. Health
2.1 Basic Checks
SCNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SCNX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SCNX has been increased compared to 5 years ago.
Compared to 1 year ago, SCNX has an improved debt to assets ratio.
2.2 Solvency
SCNX has an Altman-Z score of -0.99. This is a bad value and indicates that SCNX is not financially healthy and even has some risk of bankruptcy.
SCNX has a Altman-Z score of -0.99. This is comparable to the rest of the industry: SCNX outperforms 42.86% of its industry peers.
SCNX has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.03, SCNX perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.99 |
ROIC/WACCN/A
WACC10.25%
2.3 Liquidity
SCNX has a Current Ratio of 0.11. This is a bad value and indicates that SCNX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.11, SCNX is doing worse than 94.29% of the companies in the same industry.
A Quick Ratio of 0.11 indicates that SCNX may have some problems paying its short term obligations.
SCNX has a worse Quick ratio (0.11) than 94.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.11 | ||
| Quick Ratio | 0.11 |
3. Growth
3.1 Past
SCNX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.26%.
The Revenue for SCNX has decreased by -97.10% in the past year. This is quite bad
Measured over the past years, SCNX shows a very negative growth in Revenue. The Revenue has been decreasing by -55.05% on average per year.
EPS 1Y (TTM)-25.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.45%
Revenue 1Y (TTM)-97.1%
Revenue growth 3Y-76.01%
Revenue growth 5Y-55.05%
Sales Q2Q%-100%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
SCNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
SCNX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SCNX (11/21/2025, 1:36:26 PM)
0.5484
-0.01 (-1.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners1.56%
Inst Owner Change319.34%
Ins Owners11.91%
Ins Owner ChangeN/A
Market Cap11.59M
Revenue(TTM)128.30K
Net Income(TTM)-20.13M
Analysts82.86
Price TargetN/A
Short Float %7.54%
Short Ratio0.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend3.08
Dividend Growth(5Y)N/A
DP-10.87%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 90.32 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.15 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.87
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0.01
BVpS3.68
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.3% | ||
| ROE | -25.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 5.77% | ||
| FCFM | N/A |
ROA(3y)-75.75%
ROA(5y)-69.08%
ROE(3y)-1244.95%
ROE(5y)-781.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-54.95%
GM growth 5Y-41.74%
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 14.48% | ||
| Cap/Sales | 9.35% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.11 | ||
| Quick Ratio | 0.11 | ||
| Altman-Z | -0.99 |
F-Score2
WACC10.25%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.45%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-97.1%
Revenue growth 3Y-76.01%
Revenue growth 5Y-55.05%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5015.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26676.4%
OCF growth 3YN/A
OCF growth 5YN/A
SCIENTURE HOLDINGS INC / SCNX FAQ
What is the ChartMill fundamental rating of SCIENTURE HOLDINGS INC (SCNX) stock?
ChartMill assigns a fundamental rating of 1 / 10 to SCNX.
Can you provide the valuation status for SCIENTURE HOLDINGS INC?
ChartMill assigns a valuation rating of 0 / 10 to SCIENTURE HOLDINGS INC (SCNX). This can be considered as Overvalued.
How profitable is SCIENTURE HOLDINGS INC (SCNX) stock?
SCIENTURE HOLDINGS INC (SCNX) has a profitability rating of 1 / 10.
What is the financial health of SCIENTURE HOLDINGS INC (SCNX) stock?
The financial health rating of SCIENTURE HOLDINGS INC (SCNX) is 1 / 10.